Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Proc Natl Acad Sci U S A ; 106(49): 20936-41, 2009 Dec 08.
Artigo em Inglês | MEDLINE | ID: mdl-19926863

RESUMO

Perturbation of lipid second messenger networks is associated with the impairment of synaptic function in Alzheimer disease. Underlying molecular mechanisms are unclear. Here, we used an unbiased lipidomic approach to profile alkylacylglycerophosphocholine second messengers in diseased tissue. We found that specific isoforms defined by a palmitic acid (16:0) at the sn-1 position, namely 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (C16:0 PAF) and 1-O-hexadecyl-sn-glycero-3-phosphocholine (C16:0 lyso-PAF), were elevated in the temporal cortex of Alzheimer disease patients, transgenic mice expressing human familial disease-mutant amyloid precursor protein, and human neurons directly exposed to amyloid-beta(42) oligomers. Acute intraneuronal accumulation of C16:0 PAF but not C16:0 lyso-PAF initiated cyclin-dependent kinase 5-mediated hyperphosphorylation of tau on Alzheimer disease-specific epitopes. Chronic elevation caused a caspase 2 and 3/7-dependent cascade resulting in neuronal death. Pharmacological inhibition of C16:0 PAF signaling, or molecular strategies increasing hydrolysis of C16:0 PAF to C16:0 lyso-PAF, protected human neurons from amyloid-beta(42) toxicity. Together, these data provide mechanistic insight into how disruptions in lipid metabolism can determine neuronal response to accumulating oligomeric amyloid-beta(42).


Assuntos
Peptídeos beta-Amiloides/metabolismo , Neurônios/metabolismo , Neurônios/patologia , Fragmentos de Peptídeos/metabolismo , Fosfatidilcolinas/metabolismo , Transdução de Sinais , Proteínas tau/metabolismo , Idoso , Doença de Alzheimer/metabolismo , Doença de Alzheimer/patologia , Peptídeos beta-Amiloides/química , Peptídeos beta-Amiloides/toxicidade , Animais , Calpaína/metabolismo , Caspases/metabolismo , Sobrevivência Celular/efeitos dos fármacos , Citoproteção/efeitos dos fármacos , Retículo Endoplasmático/efeitos dos fármacos , Retículo Endoplasmático/enzimologia , Retículo Endoplasmático/patologia , Ativação Enzimática/efeitos dos fármacos , Epitopos/imunologia , Quinase 3 da Glicogênio Sintase/metabolismo , Humanos , Espaço Intracelular/efeitos dos fármacos , Espaço Intracelular/metabolismo , Camundongos , Camundongos Transgênicos , Fragmentos de Peptídeos/química , Fragmentos de Peptídeos/toxicidade , Éteres Fosfolipídicos/metabolismo , Fosforilação/efeitos dos fármacos , Estrutura Quaternária de Proteína , Transdução de Sinais/efeitos dos fármacos , Estresse Fisiológico/efeitos dos fármacos
2.
J Clin Invest ; 115(7): 1828-38, 2005 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15937550

RESUMO

Inhibitors of HIV protease have been shown to have antiapoptotic effects in vitro, yet whether these effects are seen in vivo remains controversial. In this study, we have evaluated the impact of the HIV protease inhibitor (PI) nelfinavir, boosted with ritonavir, in models of nonviral disease associated with excessive apoptosis. In mice with Fas-induced fatal hepatitis, Staphylococcal enterotoxin B-induced shock, and middle cerebral artery occlusion-induced stroke, we demonstrate that PIs significantly reduce apoptosis and improve histology, function, and/or behavioral recovery in each of these models. Further, we demonstrate that both in vitro and in vivo, PIs block apoptosis through the preservation of mitochondrial integrity and that in vitro PIs act to prevent pore function of the adenine nucleotide translocator (ANT) subunit of the mitochondrial permeability transition pore complex.


Assuntos
Apoptose/efeitos dos fármacos , Inibidores da Protease de HIV/farmacologia , Translocases Mitocondriais de ADP e ATP/antagonistas & inibidores , Animais , Anticorpos/administração & dosagem , Modelos Animais de Doenças , Feminino , Hepatite/tratamento farmacológico , Hepatite/patologia , Humanos , Células Jurkat , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Translocases Mitocondriais de ADP e ATP/química , Modelos Moleculares , Nelfinavir/farmacologia , Ritonavir/farmacologia , Choque Séptico/tratamento farmacológico , Choque Séptico/patologia , Transdução de Sinais/efeitos dos fármacos , Acidente Vascular Cerebral/tratamento farmacológico , Acidente Vascular Cerebral/patologia
3.
Sci Rep ; 6: 19332, 2016 Jan 13.
Artigo em Inglês | MEDLINE | ID: mdl-26757638

RESUMO

Fundamental changes in the composition and distribution of lipids within the brain are believed to contribute to the cognitive decline associated with Alzheimer's disease (AD). The mechanisms by which these changes in lipid composition affect cellular function and ultimately cognition are not well understood. Although "candidate gene" approaches can provide insight into the effects of dysregulated lipid metabolism they require a preexisting understanding of the molecular targets of individual lipid species. In this report we combine unbiased gene expression profiling with a genome-wide chemogenomic screen to identify the mitochondria as an important downstream target of PC(O-16:0/2:0), a neurotoxic lipid species elevated in AD. Further examination revealed that PC(O-16:0/2:0) similarly promotes a global increase in ceramide accumulation in human neurons which was associated with mitochondrial-derived reactive oxygen species (ROS) and toxicity. These findings suggest that PC(O-16:0/2:0)-dependent mitochondrial dysfunction may be an underlying contributing factor to the ROS production associated with AD.


Assuntos
Doença de Alzheimer/metabolismo , Metabolismo dos Lipídeos , Mitocôndrias/metabolismo , Transdução de Sinais , Doença de Alzheimer/genética , Doença de Alzheimer/patologia , Peptídeos beta-Amiloides/metabolismo , Linhagem Celular , Células Cultivadas , Ceramidas/metabolismo , Perfilação da Expressão Gênica , Humanos , Metabolismo dos Lipídeos/genética , Alvo Mecanístico do Complexo 2 de Rapamicina , Potencial da Membrana Mitocondrial , Mitocôndrias/genética , Complexos Multiproteicos/metabolismo , Neurônios/metabolismo , Fases de Leitura Aberta , Estresse Oxidativo , Espécies Reativas de Oxigênio/metabolismo , Serina-Treonina Quinases TOR/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA